HOMEPostContact Us
Posted January 08. 2014 11:43AM

NH firm's chewable tablet might offer new help for diabetes patients

Click headline or here to open angled item
PAZ320 is a non-systemic, non-toxic chewable drug candidate that is designed to inhibit enzymes that release glucose from complex carbohydrates in foods during digestion. In a Phase IIa study last year, 45 percent of Type 2 diabetes patients taking metformin responded to PAZ320 with a 40 percent reduction of post-meal glucose in the blood.